Clinical Trials Browser

Phase 1/2 × tislelizumab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

29 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

44 enrolled

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors